



Consolidated Financial Statements for the Year Ended March 31, 2020
FY2020 (April 1, 2019 - March 31, 2020) [UNAUDITED]

May 14, 2020

Company name: Takara Bio Inc.
 Stock exchange listings: Tokyo Stock Exchange (1st section)
 Code number: 4974
 URL: <http://www.takara-bio.co.jp>
 Company representative: Koichi Nakao, President
 Contact: Takuya Kakemi, General Manager of Corporate Management Division, Executive Officer
 Tel. (077) 565-6970

Scheduled date of general shareholders' meeting: June 23, 2020
 Scheduled date of starting delivery of dividends: June 24, 2020
 Scheduled date of annual securities report filing date: June 26, 2020

Supplementary documents of the financial results: Yes
 Financial results information meeting: Yes

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.

2. Amounts are rounded down to the nearest million yen.

1. Results for the year ended March 31, 2020 (Apr. 1, 2019 – Mar. 31, 2020)

(1) Consolidated operating results

(Percentages indicate changes from the same period of the previous fiscal year.)

	Year ended Mar. 31, 2020		Year ended Mar. 31, 2019	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	34,565	(3.6)	35,841	10.9
Operating profit	6,274	14.8	5,463	53.7
Ordinary profit	6,347	12.1	5,665	46.7
Net income (loss) attributable to owners of parent	3,819	4.4	3,657	56.6
Net income per share (in yen)	31.72		30.38	
Fully diluted net income per share (in yen)	—		—	
(Note) Comprehensive income	3,216	18.9%	2,705	10.2%
(Reference) Equity in earnings of affiliates	—		—	

(2) Consolidated financial position

	As of Mar. 31, 2020	As of Mar. 31, 2019
	(Millions of yen)	(Millions of yen)
Total assets	75,009	71,040
Net assets	66,591	64,095
Equity ratio (%)	88.7	90.1
Net assets per share (in yen)	552.23	531.57
(Reference) Equity	66,496	64,009

(3) Consolidated cash flow

	Year ended Mar. 31, 2020	Year ended Mar. 31, 2019
	(Millions of yen)	(Millions of yen)
Cash flow from operating activities	6,339	5,783
Cash flow from investing activities	(212)	(5,576)
Cash flow from financing activities	(946)	(541)
Cash and cash equivalents, end year	14,462	9,464

2. Dividends

	Annual dividends per share in yen		
	Year ended Mar. 31, 2019	Year ended Mar. 31, 2020	Year ending Mar. 31, 2021 (Forecast)
First quarter end	—	—	—
Second quarter end	0.00	0.00	0.00
Third quarter end	—	—	—
Year end	7.00	8.00	8.00
Annual	7.00	8.00	8.00
Total dividend (Millions of Yen)	842	963	
Payout ratio (%)	23.0	25.2	37.1
Dividend on equity (%)	1.3	1.5	

3. Forecast for the year ending March 31, 2021 (Apr. 1, 2020 – Mar. 31, 2021)

(Percentages indicated changes from the same period of the previous fiscal year.)

	Six months ending Sep. 30, 2020		Year ending Mar. 31, 2021	
	(Millions of yen)	(%)		
Net sales	14,365	(12.7)	33,800	(2.2)
Operating profit	619	(79.6)	4,500	(28.3)
Ordinary profit	693	(76.6)	4,600	(27.5)
Net income attributable to owners of the parent	—	(100.0)	2,600	(31.9)
Net income per share (in yen)	0.00		21.59	

※ Others

(1) Changes in subsidiaries during the period

(Changes in specified subsidiaries resulting in change of scope) : No

Newly included: — (Name)

Excluded: — (Name)

(2) Changes in accounting policies, changes in accounting estimates, and retrospective restatement

1) Changes based on revisions of accounting standard: Yes

2) Changes other than ones based on revisions of accounting standard: No

3) Changes in accounting estimates: No

4) Restatement: No

(3) Number of outstanding shares (Common stock)

1) Number of outstanding shares at year end (Treasury stocks are included)

As of March 31, 2020 120,415,600

As of March 31, 2019 120,415,600

2) Number of treasury stocks at year end

As of March 31, 2020 —

As of March 31, 2019 —

3) Average number of outstanding shares

As of March 31, 2020 120,415,600

As of March 31, 2019 120,415,600

※ These financial statements are not subject to auditing.

※ Comment regarding appropriate use of earnings forecasts and other special notes

Forward-looking statements contained in this document are determined by the Takara Bio Company based on information currently available to the Company and include a number of uncertainties. Actual results could differ from these forecasts due to changes in conditions that occur in the future. For information regarding the above, please refer to 1. Overview of Financial Results (4) Future Outlook on page 3 of the attached document.

The Company will hold a briefing for institutional investors and analysts on May 18, 2020. The material handed out at this briefing and a review of questions and answers will be posted on our website.